Health
PharmAust’s MPL and MPLS drug candidates again indicate antiviral activity in SARS-CoV2 – Small Caps
Further pre-clinical testing of PharmAust’s (ASX: PAA) monepantel (MPL) and monepantel sulphone (MPLS) drugs continues to demonstrate antiviral activity in cultured…
Further pre-clinical testing of PharmAusts (ASX: PAA) monepantel (MPL) and monepantel sulphone (MPLS) drugs continues to demonstrate antiviral activity in cultured cell infection models of SARS-CoV2 the virus causing the global COVID-19 pandemic.
Following positive earlier results in both primate and non-primate cell cultures, Leiden University Medical Centre has carried out more tests and generated data indicating both MPL and MPLS demonstrate antiviral activity in non-human primates.
This paves…
-
General22 hours agoInternal Revenue Service starts cutting 20,000 workers
-
Noosa News22 hours agoMan killed, woman seriously injured in collision in Wongabel, Atherton Tablelands, Queensland
-
Noosa News21 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation
-
Business24 hours ago$10,000 invested in ANZ shares 5 years ago is now worth…